Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Achilles Therapeutics plc (NASDAQ:ACHL) has received a notice from Nasdaq stating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing of its American Depositary Shares (ADS) on the Nasdaq Global Select Market. The company has until March 18, 2024, to regain compliance by having the closing bid price of its ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days.
September 22, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Achilles Therapeutics has received a deficiency notice from Nasdaq regarding the minimum bid price requirement. The company has until March 18, 2024, to regain compliance.
The news of Achilles Therapeutics not meeting the minimum bid price requirement for Nasdaq listing could negatively impact investor sentiment, potentially leading to a decrease in the stock price in the short term. The company's ability to regain compliance will be a key factor to watch.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100